Scion Pharmaceuticals

About Scion Pharmaceuticals

Scion Pharmaceuticals was a biotechnology firm established in 2001, with its headquarters in Medford, MA. The company concentrated its research and development efforts on identifying and optimizing small-molecule drugs.

The primary therapeutic areas of focus for Scion Pharmaceuticals were central nervous system (CNS) disorders and cardiovascular diseases. A core component of its scientific approach was the development of ion channel modulators. The company operated within the drug discovery sector of the pharmaceutical industry, providing research services aimed at creating new medicines.

Scion Pharmaceuticals secured private funding through venture capital. The company completed a Series A funding round, raising $4 million. This was followed by a Series B round in July 2002, which brought in an additional $17.5 million. The Series B investment was led by a syndicate of investors including Life Science Partners, Gray Ghost Ventures, Neuro Ventures, AgeChem, Lancet Capital, Oxford Bioscience Partners, and Lehman Holdings. The total funding raised by the company amounted to $21.5 million. According to PitchBook data, Scion Pharmaceuticals was acquired in a merger and acquisition deal on June 17, 2005, at which point it was in Phase 1 of clinical trials.